Revascular Bio

Revascular Bio is a private Japanese biotechnology company developing vascular endothelial stem cell-based therapies for diseases driven by microvascular dysfunction and genetic protein deficiency. The company is building two main approaches: an angiogenesis therapy intended to restore micro-blood flow by transplanting vascular endothelial stem cells, and an angiocrine therapy designed to provide durable protein supply for gene-deficiency disorders, potentially incorporating gene editing. Its disclosed disease focus includes chronic wounds and intractable skin ulcers, severe lower limb ischemia, cerebrovascular dementia, hemophilia, lysosomal diseases, and breast reconstruction applications. Revascular Bio is rooted in Osaka University science, particularly discoveries around CD157-positive endothelial stem cells and organ-specific vascular regeneration. The company appears to be in the preclinical stage and is advancing a broader platform around vascular regeneration and endothelial cell-based protein production.